4/7/2023 0 Comments Ambify short code![]() In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. No dosage adjustment is required for patients with mild to moderate hepatic impairment. Tics associated with Tourette's disorder: the safety and efficacy of ABILIFY in children and adolescents 6 to 18 years of age have not yet been established. Irritability associated with autistic disorder: the safety and efficacy of ABILIFY in children and adolescents aged below 18 years have not yet been established. Therefore, ABILIFY is not recommended for use in patients below 13 years of age. Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring. ![]() ![]() Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant adverse reactions including EPS related events, somnolence, fatigue and weight gain. The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks. Treatment should be initiated at 2 mg (using ABILIFY oral solution 1 mg/ml) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older: the recommended dose for ABILIFY is 10 mg/day administered on a once-a-day schedule without regard to meals. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose.ĪBILIFY is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy. ABILIFY is effective in a dose range of 10 to 30 mg/day. When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg. Schizophrenia in adolescents aged 15 years and older: the recommended dose for ABILIFY is 10 mg/day administered on a once-a-day schedule without regard to meals. ![]() Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status. Recurrence prevention of manic episodes in Bipolar I Disorder: for preventing recurrence of manic episodes in patients, who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. The maximum daily dose should not exceed 30 mg. Some patients may benefit from a higher dose. Manic episodes in Bipolar I Disorder: the recommended starting dose for ABILIFY is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy. Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. Schizophrenia: the recommended starting dose for ABILIFY is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |